The Antiepileptic Drugs Market, estimated at USD 7.48 Bn in 2025, is expected to exhibit a CAGR of 3.3% and reach USD 9.39 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key market players are focusing on adoption of inorganic growth strategies such as collabortions, and this is anticipated to drive the global Antiepileptic Drugs Market growth over the forecast period. For instance, in December 2025, UCB S.A, a global biopharmaceutical company, and Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, announced a strategic collaboration for the identification of small molecule therapies as possible treatments for KCNT1-related epilepsies based on Praxis' PRAX-020 program. Under the conditions of the collaboration, UCB S.A has the exclusive option to in-license global development and commercialization rights to any resulting KCNT1 small molecule development candidate.
Global Antiepileptic Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding the transportation from one place to another.
According to the Clinicaltrial.gov, in April 2025, there were more than 2,850 trials and approximately 900,000 patients enrolled at trial sites in the regions that were in partial or complete lockdown due to COVID-19 restrictions. While, the Research & Development (R&D) labs operated at below 50% of the normal capacity across the globe. Many companies with drug candidates for the treatment of epilepsy prioritized clinical trials based on their significant evidence of clinical activity and with held early-phase clinical trials, namely Phase I trials. Many research centers decided to freeze new trials and have stopped in-patient studies. Different pharmaceutical companies have also decided to delay the start of new clinical trials, suspended the enrollment in some trials, and have postponed the initiation of new sites in the case of trials continuing enrollment. Thus, the COVID-19 pandemic hampered the market development owing to cancellation of several ongoing clinical trials.
Global Antiepileptic Drugs Market: Key Developments
On February 7, 2025, Penn Medicine, a world-renowned academic medical center based in Philadelphia, U.S., and Children's Hospital of Philadelphia (CHOP), annouced that thet received donation of US$ 25 Mn from an undiscosed donor. This amount will be utilized to establish the Center for Epilepsy and Neurodevelopmental Disorders (ENDD), accelerating the collaborative research in genetic therapies for neurodevelopmental disorders. ENDD initially focused on developing medicines for disorders caused by mutations in the STXBP1 and SYNGAP1 genes, which are connected to abnormal brain function, intellectual disability, epilepsy, and motor and behavioral deficits.